Humalog Mix 25, 100 me/ml suspension 3 ml quikpen syringe pen cartridges 5 pcs

Hypoglycemic drug, a combination of fast- and medium-acting insulin analogues. Humalog^® Mix 25 is a DNA recombinant human insulin analog and is a ready-mix consisting of a solution of insulin lispro (a fast-acting human insulin analog) and an insulin lispro protamine suspension (a medium-acting human insulin analog).

The main action of lispro insulin is to regulate glucose metabolism. In addition, it has anabolic and anti-catabolic effects on various tissues of the body. In muscle tissue there is an increase of glycogen, fatty acids, glycerol, increased protein synthesis and increased consumption of amino acids, but there is a decrease of glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and release of amino acids.

Lispro insulin has been shown to be equimolar to human insulin, but its action is faster and lasts for a shorter time. It has an onset of action about 15 minutes later than normal human insulin and could be injected immediately before a meal (0-15 minutes before the meal). After Humalog Mix 25 injection, there is a rapid onset of action and early reaching the peak of insulin lispro activity. The action profile of insulin lispro protamine is similar to that of regular isophan insulin with a duration of action of approximately 15 hours.

Indications

Diabetes mellitus requiring insulin therapy.

Pharmacological effect

Hypoglycemic drug, a combination of insulin analogues with rapid and medium duration of action. Humalog® Mix 25 is a DNA recombinant analogue of human insulin and is a ready-made mixture consisting of a solution of insulin lispro (a fast-acting analogue of human insulin) and a suspension of insulin lispro protamine (an analogue of human insulin with an average duration of action).

The main effect of insulin lispro is the regulation of glucose metabolism. In addition, it has anabolic and anti-catabolic effects on various tissues of the body. In muscle tissue, there is an increase in the content of glycogen, fatty acids, glycerol, increased protein synthesis and an increase in amino acid consumption, but at the same time there is a decrease in glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid release.

Insulin lispro has been shown to be equimolar to human insulin, but its action is faster and lasts for a shorter time. The onset of action of the drug is approximately 15 minutes, which allows it to be administered immediately before meals (0-15 minutes before meals), compared to regular human insulin. After subcutaneous injection of Humalog Mix 25, a rapid onset of action and early peak activity of insulin lispro are observed. The action profile of insulin lispro protamine is similar to that of regular isophane insulin, with a duration of action of approximately 15 hours.

Special instructions

Transferring a patient to another type or drug of insulin with a different trade name should occur under strict medical supervision. Changes in potency, brand (manufacturer), type (eg, Regular, NPH), species (animal, human, human insulin analogue) and/or production method (DNA recombinant insulin or animal-derived insulin) may require dosage adjustments.

Active ingredient

Insulin lispro biphasic

Composition

1 ml of suspension contains:

Contraindications

Hypoglycemia; hypersensitivity to the components of the drug.

Side Effects

Side effect associated with the main effect of the drug: most often – hypoglycemia. Severe hypoglycemia can lead to loss of consciousness and, in extreme cases, death.

Allergic reactions: local allergic reactions are possible – redness, swelling or itching at the injection site (usually disappear within a few days or weeks; in some cases, these reactions can be caused by reasons not related to insulin, for example, skin irritation with an antiseptic or improper injection); systemic allergic reactions (occur less frequently, but are more serious) – generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, tachycardia, increased sweating. Severe cases of systemic allergic reactions can be life-threatening.

In rare cases of severe allergy to Humalog Mix 25, immediate treatment is required. A change in insulin or desensitization may be required.

Local reactions: with long-term use, lipodystrophy may develop at the injection site.

Interaction

The hypoglycemic effect of Humalog Mix 25 is reduced when administered simultaneously with the following drugs: oral contraceptives, corticosteroids, thyroid hormone preparations, danazol, beta2-adrenergic agonists (including ritodrine, salbutamol, terbutaline), thiazide diuretics, lithium preparations, chlorprothixene, diazoxide, isoniazid, nicotinic acid, phenothiazine derivatives.

Overdose

Symptoms: hypoglycemia, accompanied by the following symptoms – lethargy, increased sweating, tachycardia, headache, vomiting, confusion. Under certain conditions, such as long-term diabetes or intensive control of diabetes, the warning signs of hypoglycemia may change.

Storage conditions

List B. The drug should be stored out of the reach of children at a temperature of 2° to 8°C; do not freeze, protect from direct sunlight and heat.

The drug in use in the cartridge should be stored at a temperature not exceeding 30°C for no more than 28 days.

Shelf life

2 years.

Manufacturer

Lilly France, France